Evotec SE(EVO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 46 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
EVO Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Evotec SE (EVO), a Healthcare sector company. EVO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 46 institutional filers currently hold this stock. Top institutional holders of EVO by reported 13-F value include DCF Advisers, WCM INVESTMENT MANAGEMENT, ABC ARBITRAGE SA, based on the most recent SEC filings. EVO trades on the Nasdaq exchange and files with the SEC under CIK 1412558. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evotec SE directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+2.0% YoYTotal Assets
-15.1% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $797.0M +2.0% | $781.4M +4.0% | $751.4M +21.6% | $618.0M +23.4% | $500.9M +12.2% | $446.4M |
| Total Assets | $1.91B -15.1% | $2.25B -0.2% | $2.26B +1.0% | $2.24B +52.8% | $1.46B | — |
Get alerted when EVO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Evotec SE including:
Top Institutional Holders of EVO
DCF Advisers, LLC
$3.0M1,079,024 shWCM INVESTMENT MANAGEMENT, LLC
$1.9M671,884 shABC ARBITRAGE SA
$1.0M371,936 shOptiver Holding B.V.
$902.0K322,153 shMORGAN STANLEY
$576.1K205,763 shLPL Financial LLC
$464.9K166,045 shENVESTNET ASSET MANAGEMENT INC
$390.9K139,596 shOLD MISSION CAPITAL LLC
$106.5K38,032 shPathstone Holdings, LLC
$100.2K35,779 shFore Capital, LLC
$87.8K31,355 sh
| Fund | Value | Shares |
|---|---|---|
| DCF Advisers, LLC | $3.0M | 1,079,024 |
| WCM INVESTMENT MANAGEMENT, LLC | $1.9M | 671,884 |
| ABC ARBITRAGE SA | $1.0M | 371,936 |
| Optiver Holding B.V. | $902.0K | 322,153 |
| MORGAN STANLEY | $576.1K | 205,763 |
| LPL Financial LLC | $464.9K | 166,045 |
| ENVESTNET ASSET MANAGEMENT INC | $390.9K | 139,596 |
| OLD MISSION CAPITAL LLC | $106.5K | 38,032 |
| Pathstone Holdings, LLC | $100.2K | 35,779 |
| Fore Capital, LLC | $87.8K | 31,355 |
More Healthcare Companies
View all Healthcare →Put EVO on your watchlist
Track score changes the day Evotec SE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EVO a good stock to buy?
13F Pro's AI-powered analysis of Evotec SE (EVO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EVO are available on the EVO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EVO is classified as a small company.
Which hedge funds own EVO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EVO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evotec SE's investment landscape.